Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants


Last updated date


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Meningitis, Meningococcal
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
7-10 weeks
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy infants 7-10 weeks of age eligible to receive routine immunization


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Meningitis, MeningococcalStudy Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
  1. Herson, Queensland
  2. North Adealaide, South Australia
  3. Perth, Western Australia
18 Years+
Meningitis, MeningococcalStudy Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
7 Weeks+
Meningitis, MeningococcalA Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
  1. Huntsville, Alabama
  2. Chandler, Arizona
  3. Chandler, Arizona
  4. Tempe, Arizona
  5. Tempe, Arizona
  6. Tempe, Arizona
  7. Harrisburg, Arkansas
  8. San Diego, California
  9. San Francisco, California
  10. Vista, California
  11. DeLand, Florida
  12. Jacksonville, Florida
  13. Melbourne, Florida
  14. Melbourne, Florida
  15. South Miami, Florida
  16. Mishawaka, Indiana
  17. Council Bluffs, Iowa
  18. Bardstown, Kentucky
  19. Fremont, Nebraska
  20. Fremont, Nebraska
  21. Rochester, New York
  22. Cleveland, Ohio
  23. Dayton, Ohio
  24. Mt. Pleasant, South Carolina
  25. Bristol, Tennessee
  26. Austin, Texas
  27. Austin, Texas
  28. Dallas, Texas
  29. Fort Worth, Texas
  30. Houston, Texas
  31. Katy, Texas
  32. San Antonio, Texas
  33. Salt Lake City, Utah
  34. Salt Lake City, Utah
  35. Salt Lake City, Utah
  36. South Jordan, Utah
  37. West Jordan, Utah
  38. Burke, Virginia
  39. Charlottesville, Virginia
  40. Maroubra, New South Wales
  41. Westmead, New South Wales
  42. Sherwood, Queensland
  43. North Adelaide, South Australia
  44. Subiaco,
  45. Temuco, Araucania
  46. Santiago, Region Metropolitana
  47. Santiago, Region Metropolitana
  48. Conchali, Santiago
  49. Santiago,
  50. Jindrichuv Hradec,
  51. Jindrichuv Hradec,
  52. Jindrichuv Hradec,
  53. Plzen,
  54. Praha 2,
  55. Tynec nad Sazavou,
  56. Aarhus N,
  57. Rakvere,
  58. Tallinn,
  59. Tallinn,
  60. Tallinn,
  61. Pori,
  62. Tampere,
  63. Turku,
  64. Hamburg,
  65. Hamburg,
  66. Hamburg,
  67. Wuerzburg,
  68. Kaunas,
  69. Kaunas,
  70. Kaunas,
  71. Kaunas,
  72. Vilnius,
  73. Debica,
  74. Krakow,
  75. Krakow,
  76. Lubartow,
  77. Oborniki Slaskie,
  78. Poznan,
  79. Siemianowice Slaskie,
  80. Torun,
  81. Trzebnica,
  82. Wroclaw,
  83. Sevilla,
  84. Valencia,
  85. Malmo, SE
  86. Umeå,
10 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
Official Title  ICMJE A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age.
Brief Summary

Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines.

Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Condition  ICMJE Meningitis, Meningococcal
Intervention  ICMJE
  • Biological: Meningococcal C
  • Biological: DTP/Hib
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: April 11, 2006)
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 1998
Actual Primary Completion Date April 1998   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy infants 7-10 weeks of age eligible to receive routine immunization
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 7 Weeks to 10 Weeks   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00314041
Other Study ID Numbers  ICMJE 6029A1 D110 P500
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:Trial ManagerFor United Kingdom, [email protected]
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP